Rigel Pharmaceuticals Stock Revenue
| RIGL Stock | USD 20.33 0.70 3.33% |
Rigel Pharmaceuticals fundamentals help investors to digest information that contributes to Rigel Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rigel Stock. The fundamental analysis module provides a way to measure Rigel Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rigel Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 179.3 M | 188.2 M |
Rigel | Revenue |
Rigel Pharmaceuticals Company Revenue Analysis
Rigel Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Rigel Pharmaceuticals Revenue | 179.28 M |
Most of Rigel Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rigel Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Rigel
Projected quarterly revenue analysis of Rigel Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Rigel Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Rigel Pharmaceuticals' stock price.
Rigel Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Rigel Pharmaceuticals is extremely important. It helps to project a fair market value of Rigel Stock properly, considering its historical fundamentals such as Revenue. Since Rigel Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rigel Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rigel Pharmaceuticals' interrelated accounts and indicators.
| 0.15 | -0.38 | -0.18 | -0.03 | 0.29 | ||
| 0.15 | -0.63 | -0.44 | -0.16 | 0.56 | ||
| -0.38 | -0.63 | 0.45 | -0.31 | -0.76 | ||
| -0.18 | -0.44 | 0.45 | 0.36 | -0.78 | ||
| -0.03 | -0.16 | -0.31 | 0.36 | 0.17 | ||
| 0.29 | 0.56 | -0.76 | -0.78 | 0.17 |
Click cells to compare fundamentals
Rigel Revenue Historical Pattern
Today, most investors in Rigel Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Rigel Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Rigel Pharmaceuticals revenue as a starting point in their analysis.
Rigel Pharmaceuticals Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Rigel Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Rigel Pharmaceuticals reported 179.28 M of revenue. This is 97.65% lower than that of the Biotechnology sector and 75.87% lower than that of the Health Care industry. The revenue for all United States stocks is 98.1% higher than that of the company.
Rigel Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rigel Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rigel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rigel Pharmaceuticals by comparing valuation metrics of similar companies.Rigel Pharmaceuticals is currently under evaluation in revenue category among its peers.
Rigel Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rigel Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rigel Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Rigel Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Rigel Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Rigel Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rigel Pharmaceuticals' value.| Shares | Jpmorgan Chase & Co | 2024-12-31 | 180.5 K | Hillsdale Investment Management Inc. | 2024-12-31 | 170.1 K | Goldman Sachs Group Inc | 2024-12-31 | 166.9 K | Northern Trust Corp | 2024-12-31 | 145.8 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 139.1 K | Norges Bank | 2024-12-31 | 129.5 K | Qube Research & Technologies | 2024-12-31 | 118 K | Ing Investment Management Llc | 2024-12-31 | 108.6 K | Los Angeles Capital Management Llc | 2024-12-31 | 86 K | Blackrock Inc | 2024-12-31 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.6 M |
Rigel Fundamentals
| Return On Equity | -6.99 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 342.14 M | ||||
| Shares Outstanding | 17.86 M | ||||
| Shares Owned By Insiders | 2.84 % | ||||
| Shares Owned By Institutions | 68.52 % | ||||
| Number Of Shares Shorted | 1.35 M | ||||
| Price To Earning | (5.63) X | ||||
| Price To Book | 109.33 X | ||||
| Price To Sales | 2.10 X | ||||
| Revenue | 179.28 M | ||||
| Gross Profit | 137.25 M | ||||
| EBITDA | 28.51 M | ||||
| Net Income | 17.48 M | ||||
| Cash And Equivalents | 81.64 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 59.97 M | ||||
| Current Ratio | 2.34 X | ||||
| Book Value Per Share | 0.19 X | ||||
| Cash Flow From Operations | 31.47 M | ||||
| Short Ratio | 6.40 X | ||||
| Earnings Per Share | 0.99 X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 33.67 | ||||
| Number Of Employees | 162 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 375.66 M | ||||
| Total Asset | 163.98 M | ||||
| Retained Earnings | (1.39 B) | ||||
| Working Capital | 71.8 M | ||||
| Current Asset | 129.02 M | ||||
| Current Liabilities | 33.8 M | ||||
| Net Asset | 163.98 M |
About Rigel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rigel Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rigel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rigel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Rigel Pharmaceuticals Piotroski F Score and Rigel Pharmaceuticals Altman Z Score analysis. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 17.867 | Earnings Share 0.99 | Revenue Per Share | Quarterly Revenue Growth 0.609 | Return On Assets |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.